在随机FIRST试验中,持续治疗对新诊断多发性骨髓瘤缓解患者的获益
FIRST试验亚组分析按最佳缓解深度(完全缓解、≥非常好的部分缓解、≥部分缓解、≤疾病稳定)评估来那度胺联合低剂量地塞米松持续治疗(Rd持续)对比MPT和Rd18的获益。Rd持续较MPT和Rd18降低进展或死亡风险,完全缓解患者4年生存率在Rd持续组为81.1%,高于MPT组的70.8%,与Rd18组的76.5%相似。
要点
- Rd持续组中超过13%达到≥非常好的部分缓解的患者在治疗18个月后才达到该缓解。
- 完全缓解患者中,Rd持续较MPT降低进展或死亡风险67%,较Rd18降低61%。
- 完全缓解患者4年生存率Rd持续组81.1%,高于MPT组70.8%,与Rd18组76.5%相似。
核心结论
- 与固定疗程治疗相比,Rd持续改善了所有缓解患者(包括完全缓解患者)的疗效结局。
研究设计与样本
- 3期随机FIRST试验的亚组分析,患者按1:1:1随机分配至Rd持续、Rd18或MPT,按最佳缓解分为完全缓解(n=290)、≥非常好的部分缓解(n=679)、≥部分缓解(n=1 225)或≤疾病稳定(n=299)亚组。
- 研究对象为不适合移植的新诊断多发性骨髓瘤患者。
主要发现
- Rd持续组中超过13%以≥非常好的部分缓解为最佳缓解的患者在治疗18个月后才达到该缓解。
- 完全缓解、≥非常好的部分缓解和≥部分缓解患者中,Rd持续较MPT分别降低进展或死亡风险67%、51%和35%。
- 完全缓解、≥非常好的部分缓解和≥部分缓解患者中,Rd持续较Rd18分别降低进展或死亡风险61%、54%和38%。
- 完全缓解、≥非常好的部分缓解和≥部分缓解患者中,Rd持续组4年生存率分别为81.1%、73.1%和64.6%,MPT组分别为70.8%、59.8%和57.2%,Rd18组分别为76.5%、67.7%和62.5%。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The phase 3, randomized Frontline Investigation of Revlimid and Dexamethasone Versus Standard Thalidomide (FIRST) trial investigating lenalidomide plus low-dose dexamethasone until disease progression (Rd continuous) vs melphalan, prednisone and thalidomide for 12 cycles (MPT) and Rd for 18 cycles (Rd18) in transplant-ineligible patients with newly diagnosed multiple myeloma (NDMM) showed that Rd continuous prolonged progression-free survival and overall survival compared with MPT. A subanalysis of the FIRST trial was conducted to determine the benefits of Rd continuous in patients with NDMM based on depth of response. Patients randomized 1:1:1 to Rd continuous, Rd18 or MPT were divided into subgroups based on best response: complete response (CR; n=290), ⩾very good partial response (VGPR; n=679), ⩾partial response (PR; n=1 225) or ⩽stable disease (n=299). Over 13% of patients receiving Rd continuous who achieved ⩾VGPR as best response did so beyond 18 months of treatment. Rd continuous reduced the risk of progression or death by 67%, 51% and 35% vs MPT in patients with CR, ⩾VGPR and ⩾PR, respectively. Similarly, Rd continuous reduced the risk of progression or death by 61%, 54% and 38% vs Rd18 in patients with CR, ⩾VGPR and ⩾PR, respectively. In patients with CR, ⩾VGPR or ⩾PR, 4-year survival rates in the Rd continuous arm (81.1%, 73.1% or 64.6%, respectively) were higher vs MPT (70.8%, 59.8% or 57.2%, respectively) and similar vs Rd18 (76.5%, 67.7% and 62.5%, respectively). Rd continuous improved efficacy outcomes in all responding patients, including those with CR, compared with fixed duration treatment.
引用
- Bahlis NJ, Corso A, Mugge LO, et al. Benefit of continuous treatment for responders with newly diagnosed multiple myeloma in the randomized FIRST trial. Leukemia. 2017. PMID: 28373701. doi:10.1038/leu.2017.111
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。